These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26189467)

  • 21. Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014.
    Langsted A; Freiberg JJ; Nordestgaard BG
    Atherosclerosis; 2017 Feb; 257():9-15. PubMed ID: 28038381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Reiner Z; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):530-40. PubMed ID: 20577089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines.
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR; ;
    Rev Esp Cardiol (Engl Ed); 2014 Nov; 67(11):913-9. PubMed ID: 25443815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid Disorders: Screening and Treatment.
    Jin J
    JAMA; 2016 Nov; 316(19):2056. PubMed ID: 27838718
    [No Abstract]   [Full Text] [Related]  

  • 25. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WMM; Vlachopoulos C; Wood DA; Zamorano JL; Cooney MT;
    Eur Heart J; 2016 Oct; 37(39):2999-3058. PubMed ID: 27567407
    [No Abstract]   [Full Text] [Related]  

  • 26. The first European Guidelines focussed on: management of dyslipidaemias.
    Taylor J
    Eur Heart J; 2011 Aug; 32(16):1949-50. PubMed ID: 21841204
    [No Abstract]   [Full Text] [Related]  

  • 27. [Position of Interdisciplinary Spanish Committee for Cardiovascular Prevention about dyslipemia treatment guidelines].
    Millán Núñez-Cortés J; Lahera Juliá V; Vázquez Carrera M; Pedro-Botet J
    Clin Investig Arterioscler; 2015; 27(1):34-5. PubMed ID: 25556158
    [No Abstract]   [Full Text] [Related]  

  • 28. Northern light: a commentary on the 2009 Canadian Guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in adults.
    Schaefer EJ
    Clin Chem; 2010 Apr; 56(4):502-4. PubMed ID: 20185622
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparing Guidelines for Statin Treatment in Canada and the United States.
    Hennessy DA; Bushnik T; Manuel DG; Anderson TJ
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26175357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [ESC/EAS Guidelines for the management of dyslipidaemias].
    Reiner Ž; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegría E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs RH; Kjekshus JK; Perrone Filardi P; Riccardi G; Storey RF; David W;
    Rev Esp Cardiol; 2011 Dec; 64(12):1168.e1-1168.e60. PubMed ID: 22115524
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Semergen; 2015 Apr; 41(3):149-57. PubMed ID: 25450438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dyslipidaemia and vascular risk. A new evidence based review].
    Pallarés-Carratalá V; Pascual-Fuster V; Godoy-Rocatí D
    Semergen; 2015; 41(8):435-45. PubMed ID: 25559484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simplifying the approach to the management of dyslipidemia.
    Gaziano JM; Gaziano TA
    JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
    Shoji T
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1267-75. PubMed ID: 24288962
    [No Abstract]   [Full Text] [Related]  

  • 37. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease.
    Vaucher J; Marques-Vidal P; Preisig M; Waeber G; Vollenweider P
    Eur Heart J; 2014 Apr; 35(15):958-9. PubMed ID: 24569030
    [No Abstract]   [Full Text] [Related]  

  • 39. The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components.
    Virani SS
    Tex Heart Inst J; 2016 Aug; 43(4):313-4. PubMed ID: 27547139
    [No Abstract]   [Full Text] [Related]  

  • 40. A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?
    Dykun I; Mahabadi AA; Rassaf T
    Eur Heart J; 2020 Jun; 41(24):2331. PubMed ID: 32031601
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.